Huntington's type. We show both types of intracellular foci are formed in vivo: non-amyloidic extended polyglutamine derived inclusions and distinguish those from the presence of mature ß-amyloid fibers. We found that polyglutamines expanded above pathogenic threshold and ß-amyloid act synergistically to promote the progression of proteotoxicity in a temperature dependent manner.
ABSTRACT
Formation of proteinaceous deposits composed of abnormally aggregated proteins characterizes a range of pathological conditions. Proteinaceous inclusions detected in the neurodegenerative conditions such Huntington's chorea (HD) and Alzheimer's disease (AD) are often referred as pathognomic and regarded as causally implicated. Despite of differences in aetiology and underlying genetics, rare cases of combined HD and AD were reported and described as admixed proteinopathies. Mixed proteopathies are characterized by the co-occurrence of at least two types of abnormal aggregation-prone variants; pathological deposition of proteinaceous inclusions might however, affect different cell populations. Here, combining plaques derived from human ß-amyloid with mutant HTT-like polyglutamine inclusions in a cell-autonomous manner, we report on the Caenorhabditis elegans model for admixed proteinopathy of Alzheimer's and Huntington's type. We show both types of intracellular foci are formed in vivo: non-amyloidic extended polyglutamine derived inclusions and distinguish those from the presence of mature ß-amyloid fibers. We found that polyglutamines expanded above pathogenic threshold and ß-amyloid act synergistically to promote the progression of proteotoxicity in a temperature dependent manner.
We further, implicate the hsp-1 (the predominant C. elegans chaperone interacting with ER-routed Aß42) modulate the proteotoxic insults observed in combined proteopathy model. Our results demonstrate how the in vivo model of admixed proteopathy could be utilized to probe for human pathogenic variants confined to the same cellular type. In that perspective expanded aggregationprone polyglutamines appended with fluorescent proteins could be regarded as 'pathogenic probes' useful in the proteotoxicity assays i.e. involving ß-amyloid and possibly other comparable models of disease-associated aggregation prone variants.We anticipate models of combined proteopathies will be informative regarding the underlying pathogenesis and provide the sensitized background for sophisticated screening. For example the combinatorial effects of multiple pathogenic aggregation-prone variants could be tested against mutant backgrounds and pharmacological compounds. Furthermore, we surmise the postulated synergistic actions might explain some of the overlaps in observed progression of clinical symptoms in HD and AD. We also formulate the conjecture regarding the polyQ containing proteins as a contributing factor in degenerative conditions associated with increased ß-amyloid formation and deposition.
INTRODUCTION
Formation of proteinaceous inclusions occurs in a range of morbid conditions (Sipe et al. 2016 ). Pathological deposition of proteinaceous inclusions (often regarded as pathognomic in classical pathology) indicate for degenerative processes which may affect many cells types across tissues and organs. In particular, histopathological staining of congophilic material (inclusions reactive with Congo Red), is consistent with the deposition of abnormally aggregated proteins that share the structural properties common to amyloids (Tanskanen 2013) . While amyloidosis can be observed in various aetiologically unrelated conditions in many animal species, the amyloidal nature of congophilic material detected in an aging brain is regarded as a hallmark of Alzheimer's disease.
Alzheimer's disease is classified as 'conformational disease' together with other age-related dementias and encephalopathies including Huntington's chorea (Carrell &Lomas 1997) . Referred broadly as proteopathies, conformational diseases, are characterized by the accumulation of aggregates composed of malfolded proteins (Kopito &Ron 2000) . Accumulation of abnormally aggregated malfolded proteins set up the tissue-specific response of the chaperone system -the concept otherwise known as proteotoxicity (Ron 2002) . Increased demand for cellular chaperoning in response to a formation of abnormal proteinaceous foci appears as a common component of the pathology underlying the neurodegenerative diseases (Wyttenbach &Arrigo 2013). While the chaperone response appears as a consistent feature associated with the degenerative process involving the deposition of aberrant proteins, the overall mechanisms and pathways underlying the disease, including the amyloidosis, remain poorly understood.
Given the enormous complexity of the vertebrate nervous system as well as general inaccessibility of the brain for clinical sampling purposes, C. elegans appears as an attractive model for the pathogenesis of degenerative diseases. C. elegans cells engineered to express pathogenic variants implicated in the pathogenesis of the neurodegenerative diseases, mount the robust chaperone response to abnormally aggregated proteins (Fonte et al. 2002; Link et al. 2003) and recapitulate the key features of the progression of cell degeneration i.e. amyloidosis (Link 1995; Link et al. 2001) . Here, we report on the C. elegans model for admixed proteinopathy of Alzheimer's and Huntington's type. Both Alzheimer's disease and Huntington's chorea are associated with neurodegenerative features indicative for aberrant protein deposition observed in areas of affected brain (Spires &Hannan 2007) . Despite the above parallels, the population of affected neuronal cells, particularly in prodromal and incipient stages is very different in both diseases (Braak &Braak 1991; Vonsattel &DiFiglia 1998; reviewed in Stroo et al. 2017) reflecting to the differences in underlying genetics, exact pathology sites and the disease onset (Wenk 2003; Walker 2007) . The cases of combined proteinopathy of Alzheimer's and Huntington's type, are rare (Warner et al. 1994); Jellinger (1988) and others (references below) described Alzheimer's-type lesions in Huntington's disease. Here we utilized the genetic model organism to confine plaques derived from human ß-amyloid with mutant HTT-like polyglutamine inclusions in cell-autonomous manner.
MATERIALS AND METHODS
C. elegans strains and maintenance. Strains were maintained on NGM agar plates seeded with E.coli according to standard methods (Wood 1988) . Classic genetic methods (Brenner 1974 (Morley et al. 2002; Brignull et al. 2006; Beam et al. 2012) developed and provided by the Morimoto lab (Northwestern University)} were mated with him-6 males [him-6(e1104) CB1138 (Hodgkin et al. 1979) ]. YFP + F1 males carrying above transgenes were crossed onto unc-54p driven ß-amyloid transgene (dvIs2 II) CL2006 (Link 1995) hermaphrodites to establish doubly-transgenic 
RESULTS
We used extensively characterized C. elegans strains expressing human ß-amyloid peptide (Link 1995) and extended polyglutamines (Satyal et al. 2000) (Link et al. 2003) in comparable model of acute (smg-1ts dependent) ß-amyloid proteotoxicity. We subsequently followed the temperature-sensitive effects we observed initially in isogenic populations of doublehomozygotes, co-expressing ER-routed ß-amyloid and polyQ40-YFP propagated at 25°C for 10 days. In the laboratory settings isogenic C. elegans populations maintained on the solid agar media predate on the layer of E. coli cells spotted in the center of the plate. Evanescence of the bacterial feeding layer after several days of cultivation indicates for relatively unperturbed population growth. Conversely, the persistence of bacterial lawn is regarded as a vital parameter in genetic, RNAi, pathogen and xenobiotic assays. As presented in Fig.3 , we observed the persistence of the bacterial lawn in two concordant populations of doubly-homozygous (dvIs2
genotype (derived from independent mating groups) at day 10 of growth at non-permissive temperature. We contrast the above outcome by comparing with any of the singly-transgenic homozygous parental lines [expressing either ß-amyloid (dvIs2
presented as insets in Fig.3B and 3C] tested in parallel at 25°C. Above results suggest that, while the proteotoxic effects of ß-amyloid and expanded polyQ repeats are enhanced by the elevated temperatures, neither of the transgenes tested in singly-transgenic background is sufficient to account for severe growth decline observed when transgenes encoding for both pathogenic polypeptides are tested in combination.
We recapitulated the observed temperature-sensitive phenotype of double-transgenic lines co-expressing ß-amyloid and polyQ40-YFP by means of RNAi mediated withdrawal of HSP70A (F26D10.3). Administration, via feeding route, of the dsRNA corresponding to hsp-1 into the isogenic hermaphrodites of above double-transgenic background appeared to phenocopy the temperature-sensitive effect (data not shown, see discussion). We choose the HSP-1 since our previous report (Fonte et al. 2002 ) specified this particular homolog of human cytosolic HSP70 is one of the major human ß-amyloid interacting chaperone proteins in transgenic C. elegans expressing ER routed Aß42. In the descriptions of that work, we concluded, that in contrast to ER resident HSP70 chaperones hsp-3 and hsp-4 (Kapulkin et al. 2005) , cytosolic hsp-1 is an essential gene strictly required for growth and development and therefore abstained from the in-depth characterization of subviable RNAi phenotypes. Unexpectedly, the attempts to reproduce those original results with combined proteopathy model failed -control animals (of singly transgenic parental genotypes expressing either ß-amyloid or polyQ-YFP) exposed to hsp-1 RNAi were viable and superficially affected only mildly. The reasons possibly explaining the above inconsistency are stated and discussed in the following section. Demonstrated ability to distinguish pathogenic polyQ inclusions from β-sheet secondary protein structures characteristic of X-34 staining in the living animal emphasizes the potential relevance of our combined proteopathy model. An important advantage of our model is the entire process of amyloid fibrillarization, plaque formation and polyQ deposition can be followed in vivo.
Results of confocal sectioning reveal X-34 reactive structures co-exist with morphologically distinct intracellular inclusions formed by the pathogenic polyQ repeats in a strictly cellautonomous manner. This could be explained, provided the transgene encoding for human ß-amyloid produces ER-routed variant of β-peptide assumed to engage the intrinsic ER-cytoplasm retrograde transport (Fonte et al. 2002) ; mature fibers are observed as strictly intracellular structures found outside of the ER i.e. in the cytoplasm of cells affected by the combination of degenerative processes.
DISCUSSION
We have created the C. elegans model for admixed Huntington's and Alzheimer-type proteopathy. We found that transgenic mutant Huntington-type polyglutamine repeats expanded above pathogenic threshold co-exist with ß-amyloid containing senile plaques in a cell-autonomous manner. We established that the above disease associated aggregation-prone variants do form Huntington-type polyQ inclusions and congophilic Alzheimer's-type fibrils confined to the cells expressing the unc-54. Strikingly our results revealed the admixed expression pattern consisting of apparently, non-overlapping YFP labeled polyglutamine aggregates and distinct X-34 reactive fibrillar ß-amyloid-type lesions. Provided the HD and AD-type proteinaceous foci can be distinguished by gross morphology and overall microscopic appearance in vivo, our results suggest that the aggregation of polyQ repeats and formation of mature ß-amyloid fibers may occur independently when the process is confined to the same cell. While, at the moment, we cannot entirely exclude that some smaller oligomeric variants might co-aggregate (either directly or by engaging interaction with common ligand -perceivably background events not captured at current resolution), we demonstrated that the prominent polyQ40-YFP aggregates occupy different sub-cellular territories and could be distinguished from mature ß-amyloid fibers.
Our results indicate that the co-occurrence of ß-amyloid fibers and extended polyglutamine Q40 aggregates invoked the synergistic lethality in a temperature-dependent manner. This means that in the model of combined proteopathy of AD and HD type, the two different aggregation-prone proteins may act cooperatively to promote the cell-autonomous proteotoxicity. While our results do not specify the direction of causality, the combined proteopathy model should be informative regarding the underlying pathological processes. Considering the pathways involved, we note the temperature sensitivity have been reported in C. elegans polyglutamine model (Gidalevitz et al. 2006 ). Their findings suggest that polyglutamine expansions impair the cellular protein folding capacity, hence affect the stability of temperature-sensitive mutant protein variants. Consistently aggregation of polyglutamines expanded above the pathogenic threshold (Morley et al. 2002) could aggravate the effects of ß-amyloid-type lesions as observed in our combined proteopathy model.
In that perspective expanded aggregation-prone polyglutamines coupled with nimbly folded fluorescent proteins could be regarded as 'pathogenic probes' useful in the proteotoxicity assays (i.e. involving ß-amyloid and possibly other comparable models of disease-associated pathogenic variants of aggregation-prone polypeptides), and provide the sensitized background for sophisticated screening. Combined pathogenic effects of different aggregation-prone polypetides could be considerred in terms of proteotoxic (-kinetic / -dynamic parameters) measures.'
Contemplating the screening strategies immediately available in our combined proteopathy model, we reported on the experimental setting based feasibility evaluation of the sensitized background screening approach utilizing the RNA interference (RNAi) -a popular screening mode applied for C. elegans genome (Fire et al. 1998 ). In particular, we observed, administration via feeding route, of dsRNA corresponding to a major ß-amyloid interacting protein hsp-1 (Fonte et al. 2002) , results in RNAi mediated silencing effect that recapitulate the temperature-sensitive proteotoxicity recorded in our combined proteopathy model. Verily others (Nollen et al. 2004) , established the RNAi mediated withdrawal of hsp-1 acts as a modulator of polyQ aggregation (Teuling et al. 2011) . Remarkably, in a combinatorial screening for modifiers of ER-routed Aß42 RNAi withdrawal are expectedly pleiotropic and presumably cell-nonautonomous i.e. affect many tissues in addition to cells expressing proteotoxic polypeptides. Hence, some effects of hsp-1 RNAi might be distant to tissue-specific response to abnormal protein aggregation. Additionally, given the complexity of the chaperone network, hsp-1 RNAi withdrawal could affect the expression levels of other effector genes involved in the heat shock response -resulting in prominent secondary alternations of the compensatory type response as evidenced for ER-resident chaperones (Kapulkin et al. 2005) . While RNAi mediated withdrawal of hsp-1 does not significantly alter the ER resident hsp-4 reporter (Calfon et al. 2002) , RNAi against hsp-1 does influence the levels of hsp-16.2 reporter (Kapulkin WJ, Link CD 2002 unpublished observations; Guisbert et al. 2013 )-an another effector chaperone we specified as directly interacting with human ß-amyloid (Fonte et al. 2002) .
Provided the accepted variability of the efficacy in experimental feeding of dsRNA silencing mediators we suggest one explanation would consider a dose-dependent model where the overall output of hsp-1 RNAi withdrawal would perceivably involve alternations to gene expression at loci other than hsp-1 accounting for secondary effects. Still, we note an alternative, yet not mutually exclusive, explanation might exist 1).
. Furthermore, we remark the above considerations concerning the results of RNAi-based screening could now be independently verified implementing the CRISPR/Cas9 improvement to generate precise variants (singly or in combination) in transiently silenced candidate genes including hsp-1 discussed above. We have demonstrated previously that complex transgenic lines expressing Aß42 can be conveniently modified with CRISPR/Cas9 (Kapulkin et al. 2016) , henceforth the stable transgenic lines reported here as the combined proteopathy model await further characterization.
Dementia is a historically recognized feature common in both HD and AD (Davis et al. 2014) . Dementias are often classified as cortical (AD) or subcortical (HD) with symptoms reflecting the areas of the brain affected by degenerative lesions resulting in synaptic and neuronal loss (Salmon et al. 2007 ) leading to eventual neural system failure which drives the progression of the symptoms. The occurrence of degenerative lesions in HD and AD is a common feature in both conditions (Spires &Hannan 2007) however, due to very different aetiology and underlying genetics -the exact sites of histopathologically detected proteinaceous deposits overlap only partially, depending on the disease stage and a grade (Vonsatel et al. 1985; Braak&Braak 1991) . Provided in HD and AD the degenerative process impairs the specific neuronal subtypes -distinction relevant 1). While we can not exclude that the variability in the strength of RNAi could be affected by procedural differences (affecting the rate of cellular synthesis of siRNA, factors affecting the dsRNA uptake or stability, levels of T7 polymerase induction etc), we note the particular dsRNA encoding plasmids used were designed differently. The original report (Fonte et al. 2002) particularly in prodromal and incipient disease progression stages -we designed an experimental settings and utilized a versatile genetic model system to combine both Huntington and Alzheimertype lesions in cell-autonomous manner. Our two-component model combines the established Aß42-dependent amyloid root of an AD (Selkoe 1997; Hamley 2012; Jonsson et al. 2012 ) and expanded polyglutamine root of HD (Walker 2007; Finkbeiner 2011) . Based on the combination of two convergent degenerative pathways, we concluded polyglutamines expanded above pathogenic threshold exacerbates the Aß42-amyloid effects observable in our model; however, we do not know the direction of causality neither we do fully understand the pathological process underlying the disease mechanism. While presented results might suffer from insufficient characterization in terms of quantitative measures applied (to strictly quantify the observed phenotypes e.g. uncoordinated movement, aggregates number etc), we provided the evidence for synchronous expression of ß-amyloid and expanded polyglutamine reporter consistent with characterized unc-54 promoter specificity.
Combined proteopathies have been described in man (McIntosh et al. 1978; Vonsattel et al. 1985; Reyes &Gibbons 1985; Moss et al. 1988; Bruyn &Roos 1990; Becher et al. 1997; and Jellinger 1998 with relevants references therein), however, histopathologically confirmed descriptions of Alzheimer-type lesions in HD are sparse (Davis et al. 2014; St-Amour et al. 2017 ).
We note, our model could be directly informative for those admixed proteopathies. Further, we perceive the cell-autonomous readout might define the common denominator for the underlying disease mechanisms considered singly. Histopathologically HD and AD share extensive parallels observed at the cellular level (reviewed in Spires et al. 2007 ) albeit of different aetiology and underlying genetics. Despite the major socio-economic impact, the pathogenesis of those diseases is not understood sufficiently neither the available therapeutic interventions are efficient.
We have previously established that C. elegans ß-amyloid model recapitulate the key Alzheimer-type chaperone response (Fonte et al. 2002) , while others have demonstrated the induction of chaperone response in C. elegans model for expanded polyglutamines (Satyal et al. 2000) -apparently a convergent pathogenic feature recognized in AD and HD brain (Ehrnhoefer et al. 2011; Wyttenbach &Arrigo 2013; Brehme &Voisine 2016) . Chaperones may act as promiscuous ligands, binding both expanded polyglutamines and Aß42 in oligomeric forms, hence our combined proteopathy model might provide a better controlled background for future studies (as previously Fonte et al. utilized an unlocalized GFP as a co-IP specificity control). Moreover, our previous report implicated the retrograde transport of ER-routed Aß42 is responsible for cell-autonomous ß-amyloid formation. This appears possibly relevant, since certain perturbations to ER proteostasis have a protective effect against ß-amyloid toxicity in C. elegans AD model (Kapulkin et al 2005; Lopez 2009 ). Protective effects against polyglutamine toxicity, involving the modulation of chaperone protein response, have been reported in other model systems (reviewed in Brehme &Voisine 2016). Together, we perceive the chaperone type response is invoked in our combined proteopathy model, however the full spectrum of the response awaits further characterization.
Collectively the data argue in favor of the temperature-sensitive dose-dependent proteotoxicity model involving the depletion of the chaperone system capacity required to buffer the combined load of the aggregation-prone cargo. Given the preliminary nature of our report, presently we can not conclusively exclude the other pathogenesis mediators, such us postulated RNA-repeat toxicity pathways (Nalavade et al. 2013; Garcia et al. 2014; Marti 2016) , imposes on and contributes to the overall combined proteopathy phenotype (Li et al. 2008) . We note however, that overall length of expanded polyQ encoding (CAG) repeats used in our model might not suffice for significant RNArepeat toxicity (Finkbeiner 2011) .
A different type of combined proteopathy -of co-occurring Huntington and Parkinson type -have been described in a fly model (Pocas et al. 2015) . That model combines the effects of α-synuclein on aggregation and toxicity of expanded polyglutamines. In that model α-synuclein and polyQ do form co-aggregates and mutually modulate the proteotoxic effects. While our findings are in a substantial agreement with proposed synergistic (or additive) actions of both aggregation-prone proteins in vivo, the co-aggregation of α-synuclein and polyQ is contrasted with aggregative behaviour of extended polyglutamines in the presence of amyloid-plaques observed in our model.
Our results are consistent with the co-existence of two distinct types of proteinaceous foci; supporting the perspective when polyglutamines appended with fluorescent protein form one type of inclusion bodies (composed of less-ordered nonamyloid protein aggregates), and the other type of lesions forming X-34 reactive mature amyloid fibrils. While insoluble fibril-like structures have been attributed to aggregating polyglutamines (Sipe et al. 2016 ; OMIM#143100 and references therein) those ultrastructural characteristics do not confer properties of AD-type congophilic fibrills (DiFiglia et al. 1997 ; OMIM#104300 and references therein). As reviewed by Finkbeiner (2011) expanded polyglutamines in HD result in the visible protein accumulations, but the Huntington-type inclusion bodies are composed mostly of less-ordered nonamyloid protein aggregates.
Collectively, the main finding inferred from our combined proteopathy model suggests the Huntington-type polyQ inclusions are composed of substantially amorphous granular material distinct from mostly fibrillar AD-type X-34 reactive amyloid-plaques. Although X-34 stains postmortem human AD brains, showing 1:1 correspondence of X-34 and anti-Aß antibody staining of plaques and cerebrovascular amyloid (Styren et al. 2000) , our in vivo cell-autonomous model of combined proteopathy revealed an additional layer of proteotoxic complexity. Due to advantages of the cell-autonomous model, we uncovered at least two different types of intracellular inclusions:
amyloidic and non-amyloidic may co-exists in vivo, supporting the two-state aggregation model of pathogenesis. We suggest the accumulation of aberrant polyQ containing proteins need to be taken into account as possibly contributing factor in AD, but also in other disorders associated with increased Aß aggregation and senile plaque formation. Most notably neurodegenerative progression in Down syndrome (OMIM#190685) may be affected by perceivably rare concomitant expansion of non-amyloidic polyglutamine stretches.
Lastly, we note, our results corroborate with and pertain to several lines of available literature evidence: i.) apparently pathogenic, non-amyloidic, non-fibrillar, non-congophilic Aß plaques were detected in C. elegans (Link et al. 2003) , Drosophila (Crowther et al. 2005 ) AD models, and were described in certain cases of AD (Kumar-Singh et al. 2000) linked to APP variant (T714I). ii.) Singhrao et al. (1998) established that in AD immuno-histochemistry with anti-HTT antibody localized only with the intracellular structures but not with the mature amyloid. iii.) heritable polyQ disorders other than Huntington's chorea were proposed as contributing factor in AD (Reid et al. 2004 ) and TDP-43 dependent ALS (Elden et al. 2010 ). ). A. intracellular fibrillar ß-amyloid deposits distinctively reactive with X-34 (magenta). B. expanded polyQ40 appended with YFP (green). C. Brightfield contrast of the corresponding area. Congophilic intracellular mature ß-amyloid fibers (A. and D.) distinct from punctate cytosolic inclusions (B. and D.) formed by YFP appended onto polyQ repeats expanded above the pathogenic threshold. Detected ERrerouted ß-amyloid fibers fail to colocalize with punctate polyQ inclusions -observation consistent with amyloid plaque formation and concomitant polyQ inclusion deposition underlying and pathognomic of the cellular degeneration. Note X-34 reactive mass situated in the rostral area composed of material attached to leftover undissolved stain.
